Shockwave Medical Publishes Inaugural ESG Report

SANTA CLARA, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the publication of its inaugural Environmental, Social and Governance (ESG) report highlighting the company’s corporate responsibility and sustainability initiatives. The report includes 2021 performance highlights in key areas such as employee health and safety, diversity and inclusion, community impact, ethics and compliance, and environmental responsibility.

“Our entire global organization is committed to operating responsibly, sustainably, and transparently and I am impressed by how our teams across Shockwave have embraced the practices associated with ESG,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “At the core of our values is helping people, and the efforts associated with ESG extend these values beyond Shockwave and IVL for calcified vessels and to the broader world around us.”

Shockwave Medical’s 2021 ESG Report highlights several of the company’s ESG initiatives and accomplishments, including:

• Identification of the company’s top ESG priorities based on feedback from internal and external stakeholders;
• Establishment of an ESG Working Group and an ESG Executive Steering Committee at the company level, as well as the renaming of the Nominating and Corporate Governance Committee of the Board of Directors to the Nominating and ESG Committee;
• Launch of the Environmental Task Force, with the goal to identify opportunities to reduce the company’s carbon footprint and to become more environmentally efficient;
• Recent environmental accomplishments such as progress towards becoming ISO 14001 certified, which is on target for 2023, and establishment of a manufacturing facility in Costa Rica, a location chosen in part due to its positive environmental record;
• A corporate commitment to supporting local and international charities, including the recent support for Ukrainian refugees;
• Several initiatives related to equality, diversity and inclusion, which include the formation of Shockwave Women Achieving Together, an employee resource group dedicated to advancing the careers of women in engineering and technology positions in the medical device sector, as well as the initiation of the first prospective all-female study of coronary interventions – EMPOWER CAD – to address the underrepresentation of female patients in clinical trials related to cardiovascular disease, led by an all-female team of principal investigators.

Read the full Shockwave Medical 2021 ESG Report here.

About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Forward-Looking Statements
This press release contains statements relating to our expectations, activities, programs, goals, events or developments that we expect, believe or anticipate will or may occur, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, are statements that could be deemed forward-looking. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” and similar expressions, and the negative of these terms. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current plans, expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware.

Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: risks and uncertainties related to market conditions. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the SEC, and in our other periodic and other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com

Source: Shockwave Medical, Inc.